TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01738191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine
Description: The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01440387

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLULAVAL® QUADRIVALENT
Description: Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLULAVAL® QUADRIVALENT
Description: Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
Study: NCT04481165

Intervention type: OTHER
Intervention: Survey
Description: Oral interview and written questions
Study: NCT02716506

Intervention type: PROCEDURE
Intervention: POP surgery
Description: Any surgical procedure that is done to treat the symptomatic POP
Study: NCT03025347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants complete a resting control condition instead of a run.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants complete a 60 minute run at 70% of their maximal oxygen uptake
Study: NCT03370458

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum DR7
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
Study: NCT00208234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: 0.016 mg/kg IgE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Omalizumab
Description: Placebo
Study: NCT01193218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets low dose once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (high dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets mid-high dose once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets high dose once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day
Study: NCT00208234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Monoclonal antibody against IgE. 0.016 mg/kg IgE
Study: NCT03126955

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative CISS-MRI Sequences
Description: Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Interictal Laryngoscopy
Description: Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement

Intervention type: DIAGNOSTIC_TEST
Intervention: Pre-Operative Unilateral and Contralateral Botox
Description: Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
Study: NCT04087616

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBIT
Description: The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: waiting list
Description: Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
Study: NCT02824588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: Training mental flexibility
Study: NCT01193218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (high dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (low dose)
Description: Placebo tablets once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets mid-low dose once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (mid dose)
Description: Placebo tablets once a day
Study: NCT04012723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MY01 Continuous Compartmental Pressure Monitor
Description: The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
Study: NCT01184898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 8mg/m2/day IV
Study: NCT02824588

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet use
Description: Used as control for time spent on computer
Study: NCT03796676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF04965842
Description: 200 mg QD
Study: NCT01184898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2/day IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1000mg/m2/day IV every 24 hours for 5 days
Study: NCT02660268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pathway
Description: Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
Study: NCT02892864

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Retraining and Virtual therapy
Description: Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oro-myo-functional classical rehabilitation
Description: Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation.
Study: NCT01271023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-to-Range Automated Insulin Management System
Description: The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
Study: NCT02649361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study: NCT03121612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP therapy
Study: NCT00743990

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ointment containing camphor, eucalyptus oil, and menthol
Description: One time use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: One time use
Study: NCT02241720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Study: NCT02597205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physician-facing app and patient-facing messages
Description: A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
Study: NCT02769065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules
Study: NCT02620085

Intervention type: PROCEDURE
Intervention: blood sampling
Description: blood sampling
Study: NCT02971800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fluorescein injection 10%
Study: NCT02190409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental implant
Description: This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
Study: NCT00567697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: ranibizumab
Description: Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
Study: NCT03216655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call
Description: Investigators give a regular follow-up to participants: phone call monthly

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wechat group
Description: Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
Study: NCT02018978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Triaged HIV Prevention (CTHP)
Description: 1. HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~2. Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~3. Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~4. Incentives \& Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential.
Study: NCT00772187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: Single dose: 0.1-0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal analgesia (morphine)
Description: 0.1-0.5 mg of morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia (fentanyl)
Description: general anesthesia alone
Study: NCT02862925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal Scalp Stimulation
Description: During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention.
Study: NCT00699712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP (Chimeric natriuretic peptide)
Description: Infusion of CDNP at two of four doses
Study: NCT00699712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP (Chimeric natriuretic peptide)
Description: Infusion of CDNP at two of four doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD-NP (Chimeric natriuretic peptide)
Description: Infusion of CDNP at two of four doses
Study: NCT04291742

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cognitive vs software
Description: cognitive vs software

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cognitive vs software
Description: cognitive vs software
Study: NCT03588013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: 4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional education
Description: 4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ \< -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food
Description: If child remains WHZ \< -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy with biopsy
Description: If child remains at WHZ \< -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
Study: NCT00002575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03121612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP therapy
Study: NCT04811339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Description: Pepto bismol (bismuth subsalicylate)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bismuth Subsalicylate 262 milligram (mg) Oral Tablet, Chewable
Description: Pepto bismol (bismuth subsalicylate)
Study: NCT00002575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Study: NCT02089087

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Single dose at varying dosage levels depending on treatment assignment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: Single dose at varying dosage levels depending on treatment assignment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02287259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Study: NCT02769065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 capsules
Study: NCT02287259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Study: NCT03476655

Intervention type: DRUG
Intervention: Ibrutinib
Description: No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.

Intervention type: DRUG
Intervention: Ibrutinib
Description: No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
Study: NCT04735159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCS implanted with Precision SpectraTM
Description: Analyze the relationship between neuroimaging biomarkers and the different clinical scales and variables captured from each patient
Study: NCT03046992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH25448
Description: * Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448
Study: NCT03292471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
Study: NCT01612078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: 200mg/tab 2tablets, po, three times a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg/tab, po, three times a week.
Study: NCT04811339

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet without BSS
Description: Placebo Tablet made by P \& G to contain everything except active ingredient ( BSS)
Study: NCT04228354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Two doses of semaglutide given by subcutaneous (s.c., under the skin) injection with different drug product concentration and separated by 6 to 8 weeks
Study: NCT03201536

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional Suture
Description: Sutures

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zip3
Description: wound closure device
Study: NCT00483704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telcagepant 140 mg
Description: Telcagepant 140 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telcagepant 140 mg
Description: Telcagepant 140 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telcagepant 140 mg
Description: Telcagepant 140 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talcagepant 280 mg
Description: Telcagepant 280 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT03237780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV
Study: NCT02005627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazax Placebo
Description: This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
Study: NCT05015543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Training Program
Description: One training sessions includes an interval training on a bicycle ergometer. The second one is a strength training with exercise machines. Both trainings are supplemented by coordinative aspects.